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2 
SUMMARY 32
 Humoral response in cancer patients appears early in cancer progression and can be used for 33
diagnosis, including early detection. By using human recombinant protein and T7 phages 34
microarrays displaying colorectal cancer (CRC)-specific peptides, we previously selected 6 35
phages and 6 human recombinant proteins as tumor-associated antigens (TAAs) with high 36
diagnostic value. After completing validation in biological samples, TAAs were classified 37
according to their correlation, redundancy in reactivity patterns and multiplex diagnostic 38
capabilities. For predictor model optimization, TAAs were reanalyzed with a new set of 39
samples. A combination of three phages displaying peptides homologous to GRN, NHSL1 and 40
SREBF2 and four proteins PIM1, MAPKAPK3, FGFR4 and ACVR2B, achieved an area under the 41
curve (AUC) of 94%, with a sensitivity of 89.1% and specificity of 90.0%, to correctly predict the 42
presence of cancer. For early colorectal cancer stages, the AUC was 90%, with a sensitivity of 43
88.2% and specificity of 82.6%. In summary, we have defined an optimized predictor panel, 44
combining TAAs from different sources, with highly improved accuracy and diagnostic value for 45
colorectal cancer.  46
3 
1 Introduction 47
Colorectal cancer (CRC) is the major cause of cancer-associated mortality in developed 48
countries [1]. An early detection of the disease is critical for higher patient survival rates. The 49
most common CRC protein biomarker, CEA, is mostly adequate for advanced stages and for 50
monitoring recurrence of the disease [2, 3].  Final outcome of patients improves substantially 51
with early detection of CRC, with 5-year survival rates of 91.1%, %, 69.8% and 11.4% for 52
localized, regional and distant stages, respectively (Surveillance Epidemiology and End Results 53
(2011). National Cancer Institute. USA). 54
  In cancer, self-proteins altered before or during tumor formation and progression, can 55
elicit an immune response when they are released from the tumoral cells to the blood of the 56
patients [4-7]. These proteins can suffer point mutations, misfolding, truncation, over-57
expression, aberrant splicing or degradation as a consequence of mutations in the DNA of 58
tumoral cells [8-14]. Patients with cancer spontaneously develop a humoral response against 59
these altered tumor-associated autoantigens (TAAs), producing autoantibodies [15-17]. The 60
immune response occurs early during tumor development. Measuring levels of autoantibodies 61
in blood would allow for a non-invasive cancer diagnosis at earlier stages, providing an 62
effective method for cancer screening and preclinical diagnosis. This approach has already 63
been successfully used in other cancers [4, 15, 18-24].  64
 The development of noninvasive screening tests would represent a major advance in 65
the fight against cancer, as pre-clinical or early diagnosis are considered the best prevention to 66
reduce cancer mortality. Screening tests based on autoantibodies present in serum or plasma 67
of cancer patients are a promising alternative to fulfill this goal. Because antibodies are very 68
stable molecules and their differences between control and case samples are easier to detect, 69
we have used thehumoralresponseincancerpatients’toidentify autoantibodies and their 70
respective TAAs as biomarkers of CRC.   71
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 High-density protein microarrays overcome the limitation inherent to other methods, 72
such as SERPA [25], and increase the chances of finding new autoantibodies against low-73
abundant proteins. Only combinations of multiple TAAs will cope with the individual variability 74
and low prevalence of specific autoantibodies in cancer patients to render a diagnostic assay 75
with the sufficient sensitivity and specificity [26]. By using two different microarray 76
approaches, human recombinant protein microarrays (ProtoArray) and T7-phage microarrays, 77
we previously identified several TAAs with high CRC diagnostic potential [18, 27]. However, to 78
improve the diagnostic accuracy with a better and more robust predictor, we analyzed 79
different combinations of the identified TAAs with a new set of samples. The new set of 80
samples included a new panel of sera from CRC patients in A-D stages and healthy reference 81
controls. 82
In this study, we used 11 previously reported TAAs for optimization of the predictor 83
panel, since MST1/STK4 was coincident among both studies. We expressed and purified the six 84
full-length recombinant proteins obtained from ProtoArray™, as well as SULF1 protein, and 85
four phage-peptides derived from T7-phage microarrays. They were validated and tested by 86
ELISA with an independent cohort of samples, different from the sera used in the discovery 87
phase with the microarrays. The best TAA combination was composed of three phages and 4 88
proteins. This panel showed a high discriminatory power between CRC samples and controls 89
(AUC = 94%) for all stages as well as for early CRC detection (AUC = 90%).90
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2 Materials and methods 91
2.1 Clinical information and serum collection.  92
The Institutional Ethical Review Boards of the Centro de Investigaciones Biológicas (CIB) and 93
the Spanish National Research Council (CSIC) approved this study on biomarker discovery in 94
colorectal cancer. Written informed consent was obtained from all patients. Serum samples 95
for validation analysis were obtained from patients in the Bellvitge University Hospital & 96
Institut Catalá d´Oncología (Barcelona), Puerta de Hierro Hospital (Madrid) and Cabueñes 97
Hospital (Gijón). Sample collection was approved by the Ethical Review Boards of these 98
institutions. 99
For optimization studies, we used a new panel comprising 50 CRC samples 100
(representative of the different Dukes stages A-D) and 46 healthy reference control sera (Table 101
1). Serum samples from control subjects were selected to match the median age and the same 102
gender proportion that the CRC cohort. The median age was 70.8 years (range 23-90). All sera 103
were processed as previously described [18, 27]. Samples were handled anonymously 104
according to ethical and legal guidelines at the CSIC.105
106
2.2 Proteins and phages.  107
Proteins were either internally produced or purchased from various sources. The 6xHis fusion 108
proteins PIM1, MAPKAPK3, MST1/STK4, FGFR4, ACVR2B, SRC and SULF1 were expressed in E. 109
coli and purified by affinity chromatography on a HiTrap Chelating column (GE Healthcare) 110
followed by gel filtration on a Superdex 200 column (GE Healthcare), as previously described 111
[18, 27].  112
For amplification of T7 phages displaying CRC-specific peptides, BL21 E. coli cells were 113
grown until OD600 nm ≥ 0.4. Then, T7 phages displaying peptides for SREBF2, GRN, GTF2i and 114
NHSL1 were used to infect bacteria for 3-4 h until lysis was observed. Bacterial lysates were 115
centrifuged and phage-containing supernatants were stored at -80ºC until use. 116
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117
2.3 Dot blot and western blot analysis.  118
Dot blot analysis to determine the expression of FGFR4, SRC and MST1/STK4 in different 119
healthy and cancer tissues was performed using DiscoverLight Human Tissue Arrays (Pierce). 120
For western blot analysis, protein extracts from CRC paired tissues were prepared as described 121
[28, 29].  Briefly, 50 g of protein extracts were run in 10% SDS-PAGE and transferred to 122
nitrocellulose membranes (Hybond-C extra).  After blocking, membranes were incubated 123
overnight at 4ºC with optimized dilutions of specific mono- or polyclonal antibodies (FGFR4, 124
Santa Cruz Biotechnology; SRC, R&D Systems; MST1, Cell Signaling). Immunodetection on the 125
membranes was achieved by using peroxidase-conjugated secondary antibodies (Sigma). The 126
ECL signal was developed with SuperSignal West Femto substrate (Thermo). The abundance of 127
the proteins in dot blot and western blot assays was determined by densitometry using 128
Quantity One 1D Analysis Software v4.6 (Bio-Rad Laboratories). 129
130
2.4 ELISA tests 131
ELISA experiments with full-length recombinant proteins were performed as described before 132
[18]. Briefly, microtiter plates (Maxisorp, Nunc) were coated overnight with 0.3 g of the 133
purified proteins in 50 l of PBS. For multiplex analysis, we coated the same well with 0.3 g of 134
each protein, PIM1, MAPKAPK3 and FGFR4, in 50 l of PBS. After washing three times with 135
PBS, plates were blocked with 3% skimmed milk in PBS (MPBS) for 2 h at room temperature. 136
Following additional washing, serum samples (dilution 1:50 in 3% MPBS) were incubated for 2 137
h at room temperature. After washing, anti-human IgG peroxidase-labelled (DAKO) at a 1:3000 138
dilution in 3% MPBS was added for 2 h at room temperature. Then, the signal was developed 139
with 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma). The reaction was stopped with 140
1M H2SO4 and absorption was measured at 450 nm. To test T7 phages displaying CRC peptides, 141
7 
we used previously published protocols [27]. CEA concentration in serum was determined 142
using a specific immunoassay test kit (MP Biomedicals). 143
144
2.5 Statistical analysis 145
For the analysis of ELISA datasets, a one-tailed Student's t test was performed, assuming 146
unequal variances to assess whether the means of normal group and tumoral group were 147
statistically different from each other. Each individual marker and the combinations of 148
biomarkers were evaluated by receiver operating characteristics (ROC) curve analysis, and the 149
corresponding area under the curve (AUC) was calculated using JMP® 7 (SAS) and the JMP 150
Stepwise Regression option to eliminate unnecessary terms in the model. 151
Correlation between markers was performed to determine the overlap in the sera 152
reactivity in order to discern whether the information provided by each TAA was, or not, 153
partially redundant with other TAAs. ELISA results were plotted for all pairs of the 11 TAAs and 154
Pearson’scorrelationcalculatedforallcombinationsusingtheRstatisticalcomputingsystem155
[30].lowPearson’scorrelationwouldmeanthatthereactivitywitheachTdoesnotshow156
alinearassociationwiththereactivitytoanyotherT.WhereasahighPearson’scorrelation157
would indicate that one marker is partially redundant given the other. Therefore, it is more 158
likely that we find a better combined classifier if the correlation is small between two markers 159
than if the two markers are highly correlated. Note, however, that in some cases (see below 160
the example of GTF2i and SREBF2 phages), markers with high correlation can, however, do a 161
good patient discrimination when used together if, for instance, the ratio between the two 162
markers differs between types of patients.163
Logistic regression with variable selection using Akaike Information Criterion (AIC) was 164
bootstrapped as previously described with minor modifications [18, 27]. Bootstrapping was 165
applied to the complete procedure (i.e. including the variable selection step) to determine the 166
effect of the combination of the biomarkers together with the structural variables sex and age 167
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of the patients in order to determine their importance in the model since these variables 168
usually affect most of the biological process. Within each bootstrap replication (and with the 169
complete data set) variable selection was carried out using AIC. Logistic regression was fitted in 170
R [30] using the function "glm" (from R) andthefunction"lrm"fromthe“rms”packagefor R 171
by F. Harrell (version 3.3-3. http://CRAN.R-project.org/package=rms and [31]). Model 172
validationviabootstrapwascarriedoutwiththevalidatefunctioninthe“rms”package[31, 173
32]. Variable selection included CEA in the model in order to clarify if the model would benefit 174
of the measurement of the marker currently used in clinic.  175
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3 Results and discussion 176
3.1 Identification of seven proteins and four phage-peptides as CRC biomarkers. 177
Using two different protein microarrays approaches [18, 27], we observed 43 proteins with 178
significantly different autoantibody levels in CRC sera (p ≤ 0.04) and 43 phages differentially 179
recognized by CRC patients. A total of 11 TAAs were selected based on the statistical 180
significance and diagnostic prevalence. From this set, seven full length recombinant proteins 181
were expressed in E. coli and purified to homogeneity (Fig. 1) and four phages displaying CRC-182
specific peptides were amplified and purified. MST1/STK4, SULF1, ACVR2B, SRC, MAPKAPK3, 183
FGFR4 and PIM1 recombinant proteins and NHSL1, SREBF2, GRN and GTF2i-like phage lysates 184
were tested by ELISA to assess their ability to discriminate between CRC sera and healthy 185
control sera. We used an independent cohort of 96 samples (50 colorectal cancer, including 17 186
samples from early colorectal cancer stages (A-B), and 46 control samples (Fig. 2).  187
For individual TAAs, autoantibody titers in CRC group were significantly higher than in 188
control group by ELISA, except for ACVR2B, as expected [18] (Supplementary Table 1), p values 189
were statistically significant, except for GRN phage. Using ROC curves analysis, we observed 190
that all purified proteins and phages showed individual diagnostic potential for discriminating 191
between CRC and reference control samples, with AUCs ≥52% (Table 2). Interestingly, full-192
length recombinant proteins showed higher AUC values in comparison to phages displaying 193
CRC-specific peptide TAAs, with AUCs up to 73.2% for MAPKAPK3. The specificity and 194
sensitivity of the different markers was quite variable (Table 2). We also tested the ability of 195
the TAAs for their prediction ability according to the stage of the patients for early diagnosis 196
purposes. All the TAAs showed individual ability for discriminating early CRC samples from 197
controls, with AUCs going from 53.8% for NHSL1 phage up to 79.2% for MST1/STK4 198
(Supplementary Table 2).199
200
3.2 Expression of FGFR4, SRC and MST1/STK4 in colorectal cancer 201
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Protein lysate arrays containing tissue extracts from colon, rectum and other cancer tissues 202
along with matched controls were used to evaluate expression of FGFR4, SRC and MST1/STK4 203
in different pairs of cancer and normal tissues (Fig. 3A). Antibodies to FGFR4, SRC and 204
MST1/STK4 exhibited a higher expression in colon cancer relative to matched healthy colon. 205
MST1/STK4 also presented more expression in rectal cancer in comparison to normal rectum. 206
SRC was not detected in rectal tissues and FGFR4 was present in normal rectum but not in 207
rectal cancer. The three proteins exhibited quite different patterns of expression in other 208
normal and cancer tissues (i.e. cervix) (Fig. 3A).   209
For further confirmation, FGFR4 and SRC were analyzed by immunoblotting with 210
protein samples from colorectal cancer and reference cells (Fig. 3B) and paired 211
normal/tumoral colorectal extracts (Fig. 3C).  MST1/STK4 had been previously characterized 212
[27].  Interestingly, we observed an overexpression of FGFR4 in two metastatic cell lines 213
(KM12SM and SW48) and a lower and variable pattern in the rest of metastatic and non-214
metastatic CRC cell lines (Fig. 3B). SRC expression was quite variable among different CRC cell 215
lines with basal level of expression in reference control cell lines. No significant expression for 216
FGFR4 or SRC was observed in reference cells, except embryonic HEK293 (Fig. 3B).  FGFR4 217
expression was cancer-specific in early cancer stages, with slight overexpression in some 218
tumoral tissues, preferably at B and C Dukes´ stages. SRC expression was barely different 219
between tumor and normal adjacent tissue (Fig. 3C). Remarkably, two clear SRC bands were 220
observed. The upper band corresponded to the SRC expected migration. The origin of the 221
lower band is unclear, but it was SRC specific.   222
223
3.3 Classification of Tumor-Associated Antigens according to their reactivity with cancer 224
patients 225
Then, we studied the correlation between the identified TAAs for redundancy and 226
discrimination ability for CRC diagnosis. This information can be used to develop a multiplex 227
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test, since those with high correlation values can be used together. We plotted the ELISA 228
results for all pairs of TAAs. Many TAAs showed low correlation between them (≤0.34), 229
indicating that their reactivity was not redundant and they discriminated better CRC from 230
controls if tested separately (Supplementary Table 3). However, we found different scenarios 231
for several pairs of TAAs. MAPKAPK3 and ACVR2B showed a small linear correlation (0.34) and, 232
thus, gave together a good discriminatory ability (Fig. 4A), since the amount of redundant 233
information each one of the markers provides about the other marker is small. In contrast, 234
PIM1 and MAPKAPK3, with a correlation of 0.709, FGFR4 and PIM1 with 0.592 and FGFR4 and 235
MAPKAPK3 with 0.635, showed a very similar predictive ability in recognizing the same 236
patient’spopulation, suggesting the using each of these three markers individually and 237
separately, in the same model, would not improve the discrimination ability of a panel 238
predictor for CRC diagnosis. Therefore, PIM1, MAPKAPK3 and FGFR4 can be tested together to 239
enhance the diagnostic ability of the panel. Multiplexing the assay reduces the amount of sera 240
needed and simplifies the test. Indeed, when multiplexing FGFR4, PIM1 and MAPKAPK3, the 241
AUC, sensitivity and specificity increased to 79.7%, 84.8% and 79.6%, respectively (Table 2). For 242
early diagnosis purposes, we observed again that multiplexing these antigens produced an 243
increase in the AUC, sensitivity and specificity in comparison to the proteins separately 244
(Supplementary Table 2).  245
Regarding the correlation between the other markers, we noticed a high correlation 246
(0.82) for two phages: GTF2i and SREBF2. Phages GTF2i and SREBF2 appeared in most of the 247
multivariate models fitted (see section 3.5, for description of bootstrapping). The AUC of each 248
of these phages on their own is small, but GTF2i and SREBF2 together can do a good 249
discrimination (Fig. 4B). For a fixed absorbance level for SREBF2 (e.g., orange dot-slash 250
rectangle), the probability that a patient be considered disease-free increased with the levels 251
of GTF2i. In contrast, if we fix the level of GTF2i (e.g., green slash rectangle) the probability 252
that a patient is considered diseased increases as we increase the value of SREBF2. By using 253
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those two variables (SREBF2 and GTF2i) the two classes can be separated, as the “normals”254
tend to be those that have a high GTF2i value relative to the amount of SREBF2. Although the 255
two markers showed a high correlation (0.82), they can discriminate between tumor and 256
normal patients because the ratio GTF2i/SREBF2 was different between tumors and controls 257
(that ratio is higher for controls than tumors). Interestingly, although the ratio GTF2i/SREBF2 258
was highly discriminatory, there was not enough evidence of significant interaction (p value: 259
0.1448) to specify an interaction between them in the logistic regressions.  In summary, 260
correlation between independent variables is a property of the relationship of these 261
independent variables, but is not inherently related to the joint relationship of the 262
independent and the dependent variables (the disease status in this case) and their 263
discriminatory capability. It should be analyzed case by case. 264
265
3.4 Building an optimized predictor panel for colorectal cancer 266
Next, we investigated which combination of proteins and phages shows the best diagnostic 267
ability for CRC. ELISA data for each TAA and the combination of FGFR4, PIM1 and MAPKAPK3, 268
which were used together, were fitted to a logistic curve and performed logistic regressions. 269
Different models were produced using different combinations of phages and proteins. 270
The combination of three phages displaying peptides homologues to GTF2i, NHSL1 and 271
SREBF2 and four proteins PIM1, ACVR2B, MAPKAPK3 and FGFR4, with the data of the last 272
three proteins altogether, showed the best ability to discriminate among CRC serum samples 273
and reference sera (Fig. 5A). ROC curves obtained after combining the results for the seven 274
TAAs showed an AUC of 94%, with a sensitivity and specificity of 89.1% and 90%, respectively.  275
Interestingly, using the 7 TAAs optimized predictor with CRC serum samples 276
corresponding to early A-B stages, we found an AUC of 90%, with a sensitivity and specificity of 277
88.2% and 82.6%, respectively (Fig. 5B). With these same samples, CEA gave an AUC of 74%, 278
with a sensitivity and specificity of 82.4% and 63.0%, respectively (Fig. 5C).279
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280
3.5 Bootstrapping analysis confirmed the predictor panel  281
We performed bootstrapping (using 1000 bootstrap samples) to obtain a bias-corrected AUC 282
and to validate this TAA combination for CRC screening. The initial model included linear terms 283
for all phages and proteins, together with the gender and age of the patients. Since the gender 284
and age of the patients usually affect multiple biological processes, they were included in the 285
analysis to know if they affect the panel of biomarkers.  In addition, we also combined the 286
model with and without CEA quantification in all samples to determine if CEA levels in serum 287
could improve the model. With CEA in this model, the value of the bias-corrected AUC was 288
92.5%. The model without CEA, gave a bias-corrected AUC of 90.5%. Both models got better 289
AUC than CEA alone, which gave a bias-corrected AUC of 82.4%.  290
After variable selection, using Akaike Information Criterion, the final model with CEA 291
retained the same three phages displaying homologue peptides to GTF2i, NHSL1 and SREBF2 292
and four full-length recombinant proteins PIM1, ACVR2B, MAPKAPK3 and FGFR4 (Table 3). To 293
avoid an overestimation of the predictive capacity of the model, we obtained bias-corrected 294
estimates of the AUC, by bootstrapping the complete process of variable selection. The bias-295
corrected AUC was 91.6%. Bootstrapping also provided information on the stability of the 296
selection procedure: among the bootstrapped models, most contained between 7 and 11 297
variables. Interestingly, two of the variables appeared in all the models: GTF2i and SREBF2 298
phages. ACVR2B appeared in 96% of the models, PIM1, MAPKAPK3 and FGFR4 in 92%, CEA in 299
86% and, finally, NHSL1 phage in 75% of the models. Regarding the final model without CEA 300
after variable selection, we observed that the model contained the same variables, with a bias-301
corrected AUC of 90.5%, slightly lower than the model including CEA (Supplementary Table 4). 302
Then, we tested the value of the prediction for early diagnosis purposes. We started 303
from the best model composed of three phages and four proteins plus sex and age, as 304
structural variables. The bias-corrected AUC using bootstrapping was 90% for stages A-B. In 305
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this case, we did not include CEA in the analysis, since CEA is not recommended for early 306
diagnosis [2, 3]. If we apply the same test with the CEA values, the bias-corrected AUC was 307
74.2% for A-B. As expected our panel performed better than CEA for stages A and B.308
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4 Conclusions309
In this report, we have optimized a TAA combination to improve CRC diagnosis, starting from 310
two different panels of TAAs previously reported [18, 27]. The final combination was 311
composed of three phages and four recombinant proteins. Interestingly, SRC that was 312
excluded from this model did not show a clear overexpression in cancer respect to normal 313
samples, suggesting a potential relevance for overexpression in TAA selection. This final panel 314
gave higher specificity and sensitivity (AUC: 94%; bias-corrected AUC: 92.5%) to diagnose CRC 315
than any previously reported serum biomarkers, especially for early CRC stages (AUC: 90%; 316
bias-corrected AUC: 90%). These values are very promising for a non-invasive diagnosis of early 317
stage colon tumors. 318
 After observing a high correlation between the three markers: PIM1, MAPKAPK3 and 319
FGFR4, they were combined in a multiplex assay, instead of testing one antigen at a time. 320
However, ACVR2B and three phages were tested separately as they react with different 321
patients.  Further experiments might increase the specificity and sensitivity of the diagnostic 322
tests [20] by testing i) the use of full-length recombinant proteins instead of the corresponding 323
phages, ii) the most appropriate expression system (i.e. bacteria or insect cells) and iii) the use 324
of different tags in the fusion protein (GST or 6xHis) that could affect the binding of the 325
autoantibodies to its target.  326
In summary, we have described an improved CRC panel with a superior diagnostic 327
capacity for CRC. Furthermore, since most of the identified TAAs are kinases, studies to 328
determine if they could be new targets for therapeutic intervention in CRC are in progress.329
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Table 1. Clinical information of the colorectal cancer patients tested during the study. 424
Serum Total
Age 
(years)
Sex
Female Male
Sc
re
en
in
g 
w
it
h 
pr
ot
ei
n 
m
ic
ro
ar
ra
ys
Pr
ot
oA
rr
ay
s
Control 8
65.3 ± 
13.6 
2 6
CRC (Duke's stage 
D) 
12
64.5 ± 
12.1 
3 8
T7
-p
ha
ge
Control 8
63.5 ± 
15.6 
6 9
CRC (all stages) 15 66.3 ± 9.3 4 11
Duke's stage A 3 75.7 ± 5.3 1 2
Duke's stage B 3 62.3 ± 6.5 1 2
Duke's stage C 5
67.8 ± 
10.8 
1 4
Duke's stage D 4 60.2 ± 3.3 1 3
V
al
id
at
io
n
Control 46
60.9 ± 
11.4 
18 28
CRC (all stages) 50
70.8 ± 
15.7 
17 33
Duke's stage A 6
60.0 ± 
11.0 
3 3
Duke's stage B 11
73.0 ± 
10.1 
3 8
Duke's stage C 16
76.0 ± 
16.6 
8 8
Duke's stage D 17
68.7 ± 
12.1 
3 14
* The age of the different patients is represented as mean ± standard deviation.  425
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Table 2. TAA capacity to discriminate between CRC and control sera.426
Recombinant protein Phage Specificity (%) Sensitivity (%) AUC (%)b
FGFR4 - 61.9 71.1 69.2
MAPKAKP3 - 74.0 72.7 73.2
PIM1 - 83.3 48.1 65.2
ACVR2B - 76.2 59.6 66.6
MST1/STK4 - 71.4 63.5 69.1
SRC - 61.9 67.3 70.9
SULF1 - 78.6 62.0 67.1
PIM1-MAPKAPK3-FGFR4a - 79.6 84.8 79.7
- GRN 57.1 55.0 52.3
- GTF2i 52.2 60.1 57.3
- NHSL1 50.2 56.1 59.4
- SREBF2 69.6 54.4 61.0
a, These proteins were combined in a multiplexing assay. 427
b, AUC (%). Area under the curve in percentage.428
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Table 3. Predictor panel for colorectal cancer diagnosis of the final model after variable 429
selection with Akaike Information Criterion 430
Estimate Std. Error z value Pr(>z)
(Intercept) -6.593 3.844 -1.715 0.086
Age 0.056 0.033 1.688 0.091
NHSL1-phage 6.152 2.917 2.109 0.035*
GTF2i-phage a -10.597 3.313 -3.198 0.001**
SREBF2-phage 13.960 4.698 2.972 0.003**
PIM1, MAPKAPK3 and FGFR4 11.924 3.402 3.505 <.001***
ACVR2B b -9.578 3.324 -2.881 0.004**
Sex 1.506 0.842 1.789 0.074
CEA c 1.633 0.665 2.455 0.014*
The variable selection statistics show the contribution and significance of the phages and 431
human full-length recombinant proteins in the model. The intercept is the value of the logit, or 432
log (p/(1-p)), where p is the probability of being CRC patient, when the value of all the other 433
terms in the model is 0. The intercept, therefore, represents the differences in the probability 434
of being CRC or control patient, even if there are no effects of the independent variables. 435
Estimate, estimated coefficient (slope). A negative coefficient would indicate that the 436
probability of being CRC patient decreased when the immune response of the marker 437
increases; Std. Error, the standard error of the specified variable; z value or Wald statistic, 438
which is exactly equal to the estimated coefficient divided by its standard error; Pr(>z), p-439
value from the Wald test for that specific coefficient comparing the z-value against a standard 440
normal; * to ***, grade of significance.  441
a. GTF2i-phage coefficient is negative although its reactivity is higher in CRC than control due to 442
the high correlation in the immune response between GTF2i-phage and SREBF2-phage (see 443
legend to Fig.4B).  444
b, ACVR2B coefficient is negative because the reactivity with this marker is higher in controls 445
than in CRC patients. 446
C, CEA was included in the model to determine if CEA levels in serum could improve the model. 447
Alternatively, we also performed variable selection without CEA in the model (see 448
Supplementary Table 4).   449
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Legend to Figures 450
Figure 1. Full length-recombinant TAAs were expressed in E. coli and purified to homogeneity. 451
Recombinant proteins (1 g) were separated by 10% SDS-PAGE and stained with Coomassie 452
Blue to verify their purity. Identity of the purified proteins was confirmed by MALDI-TOF mass 453
spectrometry. 454
455
Figure  2. Workflow followed for the identification and validation of autoantibodies and their 456
respective target proteins as colorectal cancer diagnostic biomarkers using different sera 457
collection and statistical analyses. 458
459
Figure 3. Expression of SRC, MST1/STK4 and FGFR4 in different cancer samples. (A) 460
DiscoverLight Human Tissue Arrays spotted with protein lysates were probed with SRC, FGFR4 461
or MST1 specific antibodies. The tissues spotted in the microarrays are indicated at the bottom 462
of the figure. (B) Western blot analysis of colorectal cancer cell lines in comparison to 463
reference control cell lines. 50 g of cell extracts were separated by 10% SDS-PAGE and 464
transferred to nitrocellulose membranes and probed with specific antibodies to FGFR4 and 465
SRC. The abundance of each marker is represented as bar graph after quantification of WB by 466
densitometry.  Tubulin was used as loading control. (C) Western blot analysis of protein 467
extracts from paired normal (N) and tumoral (T) tissues from six CRC patients (Dukes stages A, 468
211 and 299; B, 699 and 700; and C, 704 and 713). Tissue protein extracts were resolved and 469
transferred onto nitrocellulose membranes and incubated with the specific antibodies. The 470
abundance of each marker is represented as bar graph after quantification of WB by 471
densitometry. Black triangles in SRC indicate the band that was quantified by densitometry. 472
473
Figure 4. Correlation study of redundancy between colorectal cancer TAAs. (A) Relationship 474
between MAPKAPK3, ACVR2B and status (CRC versus control). The linear correlation between 475
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MAPKAPK3 and ACVR2B was 0.34. Black curve represents the line from a logistic regression 476
model that includes only MAPKAPK3 and ACVR2B, with ACVR2B modeled as a restricted cubic 477
spline with three knots to use a non-linear, low complexity model. More knots were not used 478
to prevent overfitting. (B) Relationship between GTF2i-phage, SREBF2-phage and status (CRC 479
versus control). The discrimination of CRC and control samples using SREBF2-phage and GTF2i-480
phage was good. Although these markers show a high correlation (0.82), they can discriminate 481
CRC from control samples because of the ratio GTF2i-phage/SREBF2-phage is larger for 482
controls than CRC samples. The dotted black line separates CRC samples from controls with a 483
logistic regression model that included only GTF2i-phage and SREBF2-phage. As an illustration, 484
within the orange dot slash rectangle, the probability that a patient is control increased with 485
the levels of autoantibodies to GTF2i-phage for a fixed absorbance level of SREBF2-phage. 486
Within the green slash rectangle, the probability that a patient is CRC positive increased as the 487
reactivity with SREBF2-phage increased for a fixed absorbance level of GTF2i-phage. 488
489
Figure 5. Sensitivity and specificity of the optimized predictor panel. ROC curves were based on 490
multiplex analyses of the three phages and four proteins using a total of 96 samples (50 491
samples from CRC patients and 46 healthy reference controls. A) CRC samples versus reference 492
controls. B) CRC samples corresponding to Duke’sstagesandBversusreferencecontrols. C) 493
CEA value in CRC samples correspondingtoDuke’sstagesandBversus reference controls. 494
The corrected AUC after bootstrapping is also indicated in the figure. 495
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